Reevaluating NICE’s Cost-Effectiveness Thresholds: The QALY Debate

By João L. Carapinha

December 17, 2024

NICE (National Institute for Health and Clinical Excellence) recently commented on whether their cost-effectiveness thresholds should change, focusing on the intricate relationship between quality-adjusted life years (QALYs) and the incremental cost-effectiveness ratio (ICER). The ongoing debate about NICE’s cost-effectiveness thresholds reveals important concerns and insights relevant to healthcare technology assessment.

Ongoing Debate on QALYs

The use of QALYs in cost-effectiveness analysis remains a contentious issue. Critics argue that QALYs may not adequately capture the complexity of health outcomes and can be discriminatory, especially against specific patient groups. In NICE’s context, the debate centers on whether QALYs should be adjusted to reflect continuous economic growth and willingness to pay for innovation. Despite these discussions, QALYs continue to be a prevalent metric in the UK for evaluating health interventions.

Cost-Effectiveness Thresholds

Historically, NICE has employed a cost-effectiveness threshold range of £20,000 to £30,000 per QALY gained. This threshold is essential for determining whether new healthcare technologies offer good value for money. However, the NICE blog post argues that merely increasing the cost per QALY may not remedy access issues to innovative healthcare technologies. Rather, we highlight the need for the ICER to accurately reflect the country’s growing economic development and societal willingness to pay for innovation.

Economic Development and Willingness to Pay

The UK’s cost-effectiveness threshold has remained relatively static, which may signal a lag in the country’s willingness to invest in innovative healthcare technologies, compared to its international peers. It is crucial for these thresholds to adapt alongside economic shifts and changing societal values to maintain their relevance and effectiveness.

Positive Recommendations and Fixed Thresholds

Despite the ongoing debates, NICE has recommended positive outcomes for 86% of applications, demonstrating a generally supportive stance towards new technologies. The cost-effectiveness threshold is set to remain unchanged until 2028, which offers a degree of stability for healthcare providers and manufacturers.

Methodological Elements and Future Contributions

The continuous methodological discussions are significant, particularly regarding the adjustments of thresholds. Contributing to this discussion can enhance the process of determining appropriate cost-effectiveness thresholds. Factors such as uncertainty in the evidence base, disease burden, and alternative treatment availability all play vital roles in informing NICE’s decisions.

In summary, NICE explores the complex and multifaceted discussions surrounding cost-effectiveness thresholds and QALYs. We highlight the need for thresholds to be dynamic and reflective of broader economic and societal changes while also focussing on the importance of methodological rigor in these evaluations. The examination of NICE’s cost-effectiveness thresholds provides essential insights for further engagement in this crucial debate.

Reference url

Recent Posts

perioperative immunotherapy bladder cancer
       

FDA Approves Perioperative Immunotherapy for Bladder Cancer: A Breakthrough in MIBC Treatment

🚀 Are we witnessing a new era in bladder cancer treatment?

The FDA’s recent approval of durvalumab as the first perioperative immunotherapy for muscle-invasive bladder cancer (MIBC) could revolutionize outcomes for patients facing this formidable diagnosis. With significant improvements in event-free survival and overall survival over standard chemotherapy, this groundbreaking treatment offers new hope 🎉.

Curious about how this could shape the future of cancer care? Dive into the full article to uncover the potential impacts on clinical practice and health economics.

#SyenzaNews #oncology #HealthEconomics

value-based drug pricing
      

Optimizing Value-Based Drug Pricing in Japan with MARIE Framework

🔍 Are we pricing drugs based on true value?

The introduction of the MARIE framework in Japan revolutionizes value-based drug pricing by considering not just costs, but the actual benefits drugs provide to patients and society. This innovative approach significantly adjusts prices based on updated clinical data and allows for more equitable access to therapies.

Curious about how MARIE can reshape drug pricing and pharmaceutical innovation? Dive into the full article for insights!

#SyenzaNews #HealthEconomics #MarketAccess

modifiable risk factors
        

Targeting Shared Risk Pathways to Prevent Stroke, Dementia, and Depression

🧠 What if addressing just a few key lifestyle factors could significantly reduce the risk of stroke, dementia, and depression in older adults?

A recent systematic review has identified 17 **modifiable risk factors**, revealing the interconnected nature of these age-related brain diseases and offering crucial insights for preventive strategies. By focusing on aspects such as blood pressure management, nutrition, and physical activity, we can enhance quality of life for our aging population.

Dive into the article to explore how these findings could shape future healthcare models.

#SyenzaNews #HealthEconomics #HealthcareInnovation #DigitalTransformation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.